Target Health
Aliath Bioventures aims to impact patients’ lives and healthcare systems working with entrepreneurs to create new healthcare solutions developed by sustainable companies.
Aliath is a life sciences venture capital investor and an investment advisor to AltamarCAM specialized in the life sciences and healthcare markets. Our team advises AltamarCAM on the life sciences investment strategy and its execution, by sourcing, structuring, and developing investments.
Inspired by our mission and driven by experience, talent, and alignment.
Our team is formed of industry veterans and investment experts with extensive knowledge of the healthcare ecosystem, complementary backgrounds, and proven professional track record. We invest alongside the funds´ investors and our carry is aligned with our impact goals.
Turn Healthcare challenges into business opportunities.
We seek companies built on disruptive trends that are providing an opportunity to address unmet medical needs and the sustainability of healthcare systems.
Innovation, Intention and Impact.
Aliath Bioventures aims to provide solutions to the most pressing healthcare challenges of our times by targeting therapeutics and health technology companies, from seed to late stage. We follow our 3-i framework (innovation, intention, impact) and apply impact principles and standards.
Build better companies.
We target sustainable and competitive companies. The primary goal of ACP Aliath Bioventures II is to achieve competitive financial returns developing sustainable companies. We design protocols to help portfolio companies be sustainable and work hand in hand with their management to improve their sustainability.
binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io
binx health, a healthcare technology and diagnostics company focused on expanding Sexually Transmitted Infection
binx health Expands Nationwide Distribution of the binx io Molecular Point-of-Care Platform
binx health announced today it has entered into a non-exclusive national distribution agreement with
InBrain Neuroelectronics wins FDA breakthrough nod for intelligent network modulation system
InBrain Neuroelectronics announced today that it received FDA breakthrough device designation for its intelligent
Aliath Bioventures appoints Dr Philippe Monteyne and announces additional hires to further strengthen its Life Sciences Impact business
Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD,
New appointment
Delighted to have Pamela Klein join the board of one of the companies of
